Hologic Announces Denial Of Conceptus' Request For Injunction In Patent Infringement Suit
BEDFORD, Mass. (January 9, 2012) - Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that Conceptus, Inc.'s (Conceptus) request for an injunction barring future sales of Hologic's Adiana permanent contraception (Adiana) system has been denied and that no royalty will be due to Conceptus on such sales.
In October 2011, a jury returned a verdict in favor of Conceptus' finding that use of the Adiana system infringed certain claims of one patent. As a result of the jury verdict, Conceptus sought to permanently enjoin future sales of the Adiana system. On January 6, 2012, a judge in the United States District Court for the Northern District of California heard arguments from both parties on the issue and on January 9, 2012, issued a ruling that denied Conceptus' request. The judge further ruled that no royalties will be payable to Conceptus for future sales of the Adiana system.
"We are very pleased the judge saw fit to allow the Adiana system to stay on the market as an alternative for women seeking permanent contraception," said Mark Casey, Hologic's Senior Vice President and General Counsel. "We continue to evaluate our options in this matter, including appealing the underlying infringement verdict."
Forward-Looking Statement Disclaimer:
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about litigation activities and the anticipated impact of those activities on the Company's results of operations. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Additional proceedings, including appeals, on the referenced matters are possible which may affect the ultimate outcome of the litigation and associated liability. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic's filings with the Securities and Exchange Commission.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.
Hologic and Adiana, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Deborah R. Gordon
Vice President, Investor Relations